Department of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143-0946, USA.
J Nucl Med. 2010 Jan;51(1):31-6. doi: 10.2967/jnumed.109.067108. Epub 2009 Dec 15.
We have developed an in vivo method to quantify antibody uptake using (111)In-capromab pendetide SPECT combined with CT (SPECT/CT). Our goal was to evaluate this method for potential grading of prostate tumors.
Our phantom experiments focused on the robustness of an advanced iterative reconstruction algorithm that involves corrections for photon attenuation, scatter, and geometric blurring caused by radionuclide collimators. The conversion factors between image values and tracer concentrations (in Bq/mL) were calculated from a uniform phantom filled with an aqueous solution of (111)InCl(3) using the same acquisition protocol and reconstruction parameters as for patient studies. In addition, the spatial resolution of the reconstructed images was measured from a point source phantom. The measured spatial resolution was modeled into a point-spread function, and the point-spread function was implemented in a deconvolution-based partial-volume-error correction algorithm. The recovery capability to correctly estimate true tracer concentrations was tested using prostatelike and bladderlike lesion phantoms fitted in the modified National Electrical Manufacturers Association/International Electrotechnical Commission body phantom. Patients with biopsy-proven prostate cancer (n = 10) who underwent prostatectomy were prospectively enrolled in the preoperative SPECT/CT studies at the San Francisco Veterans Affairs Medical Center. The CT portion of SPECT/CT was used to generate CT-based attenuation maps and as an anatomic localization tool for clinical interpretation. Pathologic Gleason grades were compared with in vivo antibody uptake value (AUV) normalized by injected dose, effective half-life, and injection-scan time difference. AUVs were calculated in each lobe of the prostate gland with cylindric volumes of interest having dimensions of 1.5 cm in both diameter and height.
Reconstructed SPECT images further corrected by the deconvolution-based partial-volume-error correction could recover tracer concentrations up to 90% of true values in measurements of phantom volumes as small as 7.77 mL. From patient studies, there was a statistically significant correlation (rho = 0.71, P = 0.033) between higher AUVs (from either left or right lobe) and higher components of pathologic Gleason scores.
Our results strongly indicate potential for noninvasive prostate tumor grading using quantitative (111)In-capromab pendetide SPECT/CT.
我们开发了一种使用(111)In-capromab pendetide SPECT 结合 CT(SPECT/CT)对抗体摄取进行定量的体内方法。我们的目标是评估该方法用于潜在的前列腺肿瘤分级。
我们的体模实验侧重于先进迭代重建算法的稳健性,该算法涉及对由放射性核素准直器引起的光子衰减、散射和几何模糊进行校正。使用与患者研究相同的采集协议和重建参数,从充满(111)InCl(3)水溶液的均匀体模中计算图像值与示踪剂浓度(以 Bq/mL 计)之间的转换因子。此外,从点源体模测量重建图像的空间分辨率。将测量的空间分辨率建模为点扩散函数,并在基于反卷积的部分容积误差校正算法中实现点扩散函数。使用拟合在改良的美国国家电器制造商协会/国际电工委员会体模中的前列腺样和膀胱样病变体模测试正确估计真实示踪剂浓度的恢复能力。在旧金山退伍军人事务医疗中心进行了前瞻性术前 SPECT/CT 研究,纳入了 10 名经活检证实患有前列腺癌并接受前列腺切除术的患者。SPECT/CT 的 CT 部分用于生成 CT 基础衰减图,并作为临床解释的解剖定位工具。病理 Gleason 分级与通过注射剂量、有效半衰期和注射-扫描时间差归一化的体内抗体摄取值(AUV)进行比较。使用具有直径和高度均为 1.5cm 的圆柱体积感兴趣区在前列腺的每个叶中计算 AUV。
通过基于反卷积的部分容积误差校正进一步校正的重建 SPECT 图像可以在体积小至 7.77mL 的测量中恢复高达 90%的真实示踪剂浓度。来自患者研究的结果表明,左右叶的 AUV 值越高(rho=0.71,P=0.033)与病理 Gleason 评分的较高成分之间存在统计学显著相关性。
我们的结果强烈表明,使用定量(111)In-capromab pendetide SPECT/CT 进行非侵入性前列腺肿瘤分级具有潜力。